Key result
Cardiac contractility modulation improves peak VO2, 6-minute walk distance, and NYHA functional class, mitigating symptoms and decreasing hospitalizations in heart failure patients.
Why the study?
Heart failure often progresses despite optimal medical and device therapies, while advanced mechanical circulatory support has limited availability and substantial associated morbidity.
Does cardiac contractility modulation improve symptoms and functional capacity in patients with heart failure?
Design
Review
Loading...
May offer symptomatic benefit in select HF patients; leaves open need for RCTs to guide adoption.
Does cardiac contractility modulation improve symptoms and functional capacity in patients with heart failure?
Cardiac contractility modulation is an emerging device therapy that improves symptoms and functional capacity in heart failure patients with mild-to-moderate reduced ejection fraction.
A 2021 study conducted a review in Heart failure. Cardiac contractility modulation (CCM) was evaluated. Cardiac contractility modulation improves peak VO2, 6-minute walk distance, and NYHA functional class, mitigating symptoms and decreasing hospitalizations in heart failure patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: